Aim immunotech reports additional patient data from single-center named patient program evaluating ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data

Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and locally advanced pancreatic cancer (lapc)

AIM Ratings Summary

AIM Quant Ranking